How to reduce scalp DHT as much as possible?
    Finasteride/Dutasteride 10/9/2025

    New to Dutasteride? There is a guide in the encyclopedia. Read the guide →
    At a glance
    In this hair loss treatment regimen post, the primary subjects mentioned are
    💊 Dutasteride (oral) 0.5mg daily
    💊 Dutasteride (oral) 2.5mg daily
    💉 Testosterone (injection) 250mg cycle
    the tone is 😐 neutral.

    Other terms

    The conversation discusses reducing scalp DHT to prevent hair loss, with a focus on using dutasteride, finasteride, and other treatments like RU58841 and minoxidil. It highlights the challenges of managing hair loss while on high testosterone levels, suggesting that dutasteride may be more effective than finasteride in such cases.
    View this post in the Community →

    Similar Community Posts Join

    6 / 6 results

    Related Research

    6 / 6 results
      Clinical Updates in Hair

      research CLINICAL UPDATES IN HAIR

      19 citations , January 1997 in “Dermatologic Clinics”
      This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.
      Antiandrogens and Androgen Inhibitors in Dermatologic Treatments

      research Antiandrogens and Androgen Inhibitors

      November 2020 in “Elsevier eBooks”
      This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.
      New Therapeutics in the Management of Androgenetic Alopecia

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.